AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21537591 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 13
Study 19281503 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate transmucosal tapered-effect (TE) implants placed in molar extraction sockets with buccal bone dehiscence
Number of subjects: 30
Study 19281503 — intervention group
Group type: COMPARATOR
Intervention: Implants placed in healed molar sites (control sites)
Number of subjects: 30
Study 17562636 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (specific methods not detailed)
Number of subjects: 39
Study 17562636 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study 15105178 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential exposure to magnetic fields
Number of subjects: 44
Study 15105178 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to magnetic fields (highest exposure)
Number of subjects: 44
Study 15105178 — intervention group
Group type: COMPARATOR
Intervention: Residential exposure to magnetic fields (ER-positive breast cancer)
Number of subjects: 44
Study 15105178 — intervention group
Group type: COMPARATOR
Intervention: Residential exposure to magnetic fields (ER-negative breast cancer)
Number of subjects: 44
Study 11678784 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxy-XL 10 mg
Number of subjects: 0
Study 11678784 — intervention group
Group type: COMPARATOR
Intervention: IR-Oxy 5 mg
Number of subjects: 0
Study 9832663 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed saline solution
Number of subjects: 35
Study 9832663 — intervention group
Group type: COMPARATOR
Intervention: Room temperature saline solution
Number of subjects: 35
Study 8076768 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment (8.4-336 MU)
Number of subjects: 90
Study 8076768 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment (336 MU)
Number of subjects: 90
Study 8076768 — intervention group
Group type: COMPARATOR
Intervention: Other treatment protocols (lower dosages)
Number of subjects: 90
Study 2642538 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy for 1 year
Number of subjects: 463
Study 2642538 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 463
Study 2642538 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone for 1 year
Number of subjects: 463
Study 322648 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% solution
Number of subjects: 30
Study 322648 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 1.5% solution
Number of subjects: 30
Study 31838199 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD risk prediction model (based on age, sex, history of myocardial infarction, history of diabetes mellitus, presence of bundle branch block, N-terminal pro-brain natriuretic peptide level)
Number of subjects: 615
Study 31838199 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk classification (predicted risk of SCD ≥10%)
Number of subjects: 615
Study 31838199 — intervention group
Group type: EXPERIMENTAL
Intervention: High SCD risk prediction
Number of subjects: 615
Study 31838199 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD risk model performance
Number of subjects: 615
Study 31535715 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 759
Study 31535715 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 759
Study 28862758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab (225 mg or 675/225 mg)
Number of subjects: 133
Study 28862758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 25514103 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk/run training for 10 weeks
Number of subjects: 39
Study 25514103 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL3 isolated from MetS patients with walk/run training
Number of subjects: 39
Study 25514103 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained state)
Number of subjects: 39
Study 22908891 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ceftriaxone during induction of anesthesia
Number of subjects: 73
Study 22908891 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course oral third-generation cephalosporin after ceftriaxone until nephrostomy catheter withdrawal
Number of subjects: 73
Study 21660077 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 45 mg/day for 12 months (n = 10)
Number of subjects: 21
Study 21660077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with pioglitazone (45 mg/day) and exenatide (10 µg subcutaneously twice daily) for 12 months (n = 11)
Number of subjects: 21
Study 19588536 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 J cm(‐2) LED phototherapy
Number of subjects: 28
Study 19588536 — intervention group
Group type: COMPARATOR
Intervention: Placebo phototherapy (<1.0 J cm(‐2))
Number of subjects: 28
Study 17657403 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stent placement (CAS)
Number of subjects: 48
Study 17657403 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 48
Study 17657403 — intervention group
Group type: EXPERIMENTAL
Intervention: S100beta protein evaluation
Number of subjects: 48
Study 15541674 — intervention group
Group type: EXPERIMENTAL
Intervention: Charite artificial disc replacement
Number of subjects: 144
Study 15541674 — intervention group
Group type: COMPARATOR
Intervention: BAK anterior interbody fusion
Number of subjects: 144
Study 11566520 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of dexamethasone
Number of subjects: 104
Study 11566520 — intervention group
Group type: COMPARATOR
Intervention: No subconjunctival steroid injection
Number of subjects: 104
Study 9626918 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 12 microg
Number of subjects: 20
Study 9626918 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg
Number of subjects: 20
Study 9626918 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 96 microg
Number of subjects: 20
Study 9626918 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of formoterol
Number of subjects: 20
Study 7956746 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice interventions for alcohol misuse management
Number of subjects: 0
Study 3585263 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antibiotic ointment (neomycin, polymyxin B, bacitracin) applied twice a day
Number of subjects: 6
Study 3585263 — intervention group
Group type: COMPARATOR
Intervention: Antiseptics
Number of subjects: 6
Study 3585263 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 6
Study 3585263 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antibiotic ointment
Number of subjects: 6
Study 29526019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node biopsy followed by systematic axillary-lymph-node dissection (sALND)
Number of subjects: 1544
Study 29526019 — intervention group
Group type: COMPARATOR
Intervention: Systematic axillary-lymph-node dissection (sALND) restricted to cases with positive SLN biopsy
Number of subjects: 1544
Study 29526019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node biopsy followed by sALND
Number of subjects: 1544
Study 29526019 — intervention group
Group type: COMPARATOR
Intervention: Sentinel-lymph-node biopsy (control arm)
Number of subjects: 1544
Study 28255085 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 25
Study 28255085 — intervention group
Group type: COMPARATOR
Intervention: Sham Control (SC)
Number of subjects: 25
Study 28255085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IMT and SC)
Number of subjects: 25
Study 26073276 — intervention group
Group type: COMPARATOR
Intervention: Active ITD
Number of subjects: 8719
Study 26073276 — intervention group
Group type: COMPARATOR
Intervention: Sham ITD
Number of subjects: 8719
Study 23922399 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue self-management (FSM)
Number of subjects: 111
Study 23922399 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 111
Study 23922399 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 111
Study 21034744 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir 750 mg every 8 hours with peginterferon alfa-2a and ribavirin
Number of subjects: 161
Study 21034744 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir 1125 mg every 12 hours with peginterferon alfa-2a and ribavirin
Number of subjects: 161
Study 21034744 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir with peginterferon alfa-2b and ribavirin
Number of subjects: 161
Study 21034744 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a with ribavirin
Number of subjects: 161
Study 21034744 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2b with ribavirin
Number of subjects: 161
Study 17490759 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection during primary angioplasty (DP group)
Number of subjects: 116
Study 17490759 — intervention group
Group type: COMPARATOR
Intervention: Control group (angioplasty alone)
Number of subjects: 116
Study 16319977 — intervention group
Group type: EXPERIMENTAL
Intervention: inter-Simple Sequence Repeat (inter-SSR) PCR
Number of subjects: 18
Study 12568736 — intervention group
Group type: EXPERIMENTAL
Intervention: Jia-Wey Shiau-Yau San (JWSYS)
Number of subjects: 0
Study 12568736 — intervention group
Group type: COMPARATOR
Intervention: Continuous combined hormone replacement therapy (Premelle)
Number of subjects: 0
Study 10735980 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C-enriched diet after muscle glycogen depletion
Number of subjects: 6
Study 10735980 — intervention group
Group type: COMPARATOR
Intervention: Control group with no muscle glycogen depletion
Number of subjects: 6
Study 8725417 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam at a target plasma concentration of 150 ng/mL
Number of subjects: 20
Study 8725417 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam at a target plasma concentration of 300 ng/mL
Number of subjects: 20
Study 8725417 — intervention group
Group type: COMPARATOR
Intervention: Control of hypertension with sufentanil
Number of subjects: 20
Study 1561909 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg/d
Number of subjects: 54
Study 1561909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 3898348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg twice daily
Number of subjects: 149
Study 3898348 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergic (glycopyrrolate, 2 mg three times daily) and antacid (60 ml/day)
Number of subjects: 149
Study 3898348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 149
Study 3898348 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergic/antacid
Number of subjects: 149
Study 30539891 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed iron-folic acid (IFA) supplementation
Number of subjects: 400
Study 30539891 — intervention group
Group type: COMPARATOR
Intervention: Control group (IFA tablets without direct supervision)
Number of subjects: 400
Study 27810483 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea consumption (>40 cup-years)
Number of subjects: 2111
Study 27810483 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea consumption (endometrioid histotype)
Number of subjects: 2111
Study 27810483 — intervention group
Group type: COMPARATOR
Intervention: Coffee and caffeinated soft drinks consumption
Number of subjects: 2111
Study 27810483 — intervention group
Group type: COMPARATOR
Intervention: Any tea consumption
Number of subjects: 2111
Study 27810483 — intervention group
Group type: COMPARATOR
Intervention: Green tea consumption
Number of subjects: 2111
Study 25009139 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Stories intervention
Number of subjects: 50
Study 25009139 — intervention group
Group type: COMPARATOR
Intervention: Standard stories (control)
Number of subjects: 50
Study 22538329 — intervention group
Group type: EXPERIMENTAL
Intervention: Spotty calcification
Number of subjects: 1347
Study 22538329 — intervention group
Group type: COMPARATOR
Intervention: Intensive low-density lipoprotein cholesterol and blood pressure lowering therapy
Number of subjects: 1347
Study 20399404 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers In Motion (P-MIM) intervention
Number of subjects: 129
Study 20399404 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 129
Study 18824641 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone use
Number of subjects: 232
Study 18824641 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of Milrinone
Number of subjects: 232
Study 18824641 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 232
Study 18824641 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower preoperative ejection fraction
Number of subjects: 232
Study 18824641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 232
Study 18824641 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve surgery
Number of subjects: 232
Study 18824641 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular dysfunction
Number of subjects: 232
Study 18824641 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean pulmonary artery pressure
Number of subjects: 232
Study 17158415 — intervention group
Group type: EXPERIMENTAL
Intervention: 400,000 IU vitamin A in 2 divided doses
Number of subjects: 168
Study 17158415 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin A as a single dose plus placebo
Number of subjects: 168
Study 17158415 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 168
Study 17158415 — intervention group
Group type: COMPARATOR
Intervention: Baseline serum retinol concentration
Number of subjects: 168
Study 17158415 — intervention group
Group type: COMPARATOR
Intervention: Baseline MRDR value
Number of subjects: 168
Study 17158415 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment serum retinol concentrations
Number of subjects: 168
Study 14634738 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated knee prosthesis implantation
Number of subjects: 25
Study 14634738 — intervention group
Group type: COMPARATOR
Intervention: Free-hand knee prosthesis implantation
Number of subjects: 25
Study 14634738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both navigated and free-hand procedures
Number of subjects: 25
Study 10884642 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled injection pressure system
Number of subjects: 80
Study 10884642 — intervention group
Group type: COMPARATOR
Intervention: Conventional atraumatic syringe injection technique
Number of subjects: 80
Study 8730070 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of frequency response functions at different signal levels (stepped sine and random noise)
Number of subjects: 1
Study 8730070 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of coherence function at different signal levels (using random noise)
Number of subjects: 1
Study 8730070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hilbert transform of the estimated frequency response function
Number of subjects: 1
Study 1593854 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (0.55 g/kg/day)
Number of subjects: 14
Study 1593854 — intervention group
Group type: COMPARATOR
Intervention: High protein diet (2 g/kg/day)
Number of subjects: 14
Study 6140202 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 6-methylprednisolone
Number of subjects: 452
Study 6140202 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-methylprednisolone combined with 3 g of sulfasalazine
Number of subjects: 452
Study 6140202 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of sulfasalazine alone
Number of subjects: 452
Study 6140202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study 6140202 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of low doses of 6-methylprednisolone or the combination regimen
Number of subjects: 452
Study 31868920 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPPFrail-guided deprescribing plan
Number of subjects: 130
Study 31868920 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 130
Study 31868920 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study 30880285 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP-guided antibiotic treatment (CRP ≥50 mg·L‐1)
Number of subjects: 220
Study 30880285 — intervention group
Group type: COMPARATOR
Intervention: GOLD strategy (patient reported symptoms)
Number of subjects: 220
Study 30880285 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP-guided antibiotic treatment
Number of subjects: 220
Study 30880285 — intervention group
Group type: COMPARATOR
Intervention: GOLD strategy
Number of subjects: 220
Study 29059190 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mass drug administration (MDA) of praziquantel
Number of subjects: 75
Study 29059190 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA every 2 years
Number of subjects: 75
Study 29059190 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA every other year
Number of subjects: 75
Study 29059190 — intervention group
Group type: COMPARATOR
Intervention: Control (no MDA schedule specified)
Number of subjects: 75
Study 25806862 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated serum creatinine measurements
Number of subjects: 5210
Study 25806862 — intervention group
Group type: COMPARATOR
Intervention: Noncalibrated serum creatinine measurements
Number of subjects: 5210
Study 24258312 — intervention group
Group type: EXPERIMENTAL
Intervention: LEDT (light-emitting diode phototherapy at 630 nm; total energy density, 20.4 J/cm2)
Number of subjects: 17
Study 24258312 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO (phototherapy aimed at the muscle but turned off)
Number of subjects: 17
Study 22027847 — intervention group
Group type: EXPERIMENTAL
Intervention: Full range of motion (FULL)
Number of subjects: 40
Study 22027847 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial range of motion (PART)
Number of subjects: 40
Study 22027847 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 40
Study 19443659 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 180
Study 19443659 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 180
Study 19443659 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (denileukin)
Number of subjects: 180
Study 19443659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 180
Study 17299107 — intervention group
Group type: COMPARATOR
Intervention: Beverage containing green tea catechins, caffeine, and calcium (3 x 250-mL servings for 3 days)
Number of subjects: 31
Study 17299107 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 31
Study 16845754 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (15 weeks, 31 hours total)
Number of subjects: 40
Study 16845754 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study 11243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma leptin levels (mean, 11.1 ng/mL for boys and 19.7 ng/mL for girls in the highest quintile)
Number of subjects: 1265
Study 11243304 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and plasma leptin levels
Number of subjects: 1265
Study 11243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma leptin levels
Number of subjects: 1265
Study 9621711 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation training (10 sessions over 2 weeks)
Number of subjects: 22
Study 9621711 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 8153985 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 600 mg single dose
Number of subjects: 245
Study 8153985 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg single dose
Number of subjects: 245
Study 8153985 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg daily for 3 days
Number of subjects: 245
Study 8153985 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg daily for 5 days
Number of subjects: 245
Study 8153985 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (all dosages)
Number of subjects: 245
Study 2896600 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (1.5 mg/kg/day for one year)
Number of subjects: 20
Study 2896600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31030594 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (terbinafine 250 mg + itraconazole 200 mg)
Number of subjects: 3
Study 31030594 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Number of subjects: 3
Study 31030594 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Number of subjects: 3
Study 29737494 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss during low-calorie diet (11.3% weight loss)
Number of subjects: 52
Study 29737494 — intervention group
Group type: COMPARATOR
Intervention: Addition of 500 mg (1, 3)(1, 6)-β-glucan (BG) daily
Number of subjects: 52
Study 29737494 — intervention group
Group type: COMPARATOR
Intervention: Control group of 20 normal-weight subjects
Number of subjects: 52
Study 28430976 — intervention group
Group type: COMPARATOR
Intervention: Reboxetine (8 mg single dose)
Number of subjects: 16
Study 28430976 — intervention group
Group type: COMPARATOR
Intervention: Reboxetine (8 mg/day for 21 days)
Number of subjects: 16
Study 28430976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 26182774 — intervention group
Group type: EXPERIMENTAL
Intervention: Local steroid injection
Number of subjects: 116
Study 26182774 — intervention group
Group type: COMPARATOR
Intervention: Mini incision technique
Number of subjects: 116
Study 24129852 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool transplantation
Number of subjects: 0